Jul 12, 2022
Jeff Cleland is the Chairman, President, and CEO of Ashvattha Therapeutics, initially focusing on demonstrating the ability to deliver drugs that cross tissue barriers like the blood-brain barrier and the blood-retinal barrier to attack inflammation. The company is part of the emerging era of Hydroxyl Dendrimer Therapeutics, HDTs. While starting with ophthalmology and treating wet age-related macular degeneration and diabetic macular edema, they are also running trials with long haul COVID patients. In addition, they are investigating neurological diseases like Alzheimer's and Parkinson's with the ability to measure the amount of the drug that gets into the brain.
Jeff explains, "The secret is the platform that was developed by our founders at Johns Hopkins. It's a husband and wife team that really focused on trying to figure out how to get across tissue barriers. So, they empirically went about looking at different nanomedicine platforms, and they came across what's called a hydroxyl dendrimer platform."
"What's unique about this is the density of hydroxyls on the surface makes it look like water to the body, so when it goes into the body, it doesn't get taken up by cells or tissues unless there's inflammation present. Then as it goes by those areas of inflammation, the cells grab the hydroxyl dendrimer and take it inside. Then we could treat intercellular targets, unlike other approaches where it hits all cells."
#AshvatthaTherapeutics #HDT #HydroxylDendrimerTherapeutics #WetAgeRelatedMacularDegeneration #DiabeticMacularEdema #Inflammation #LongCOVID #COVID #Alzheimers #Parkinsons
